Zacks small cap research.

By Ann Heffron, CFA, CPA OTC:CPKF READ THE FULL CPKF RESEARCH REPORT Chesapeake Financial’s (OTC:CPKF) third quarter net earnings increased $0.5 million, or 13%, year over year to $4.2 million, while 2022’s third quarter diluted EPS rose by $0.12, or 15%, to $0.90 from $0.78 posted a year ago. Results exclude a one-time gain …By Lisa Thompson NASDAQ:GROM Fresh off a December $5.0 million capital raise and reverse split in December, Grom Social Enterprises (NASDAQ:GROM) is poised to capitalize on a number of promising initiatives over the next several months. The company now has 3.2 million in fully diluted shares and trades at a market capitalization …The details of 2Q 2023: • Revenue for the quarter came in at $1,480,388, which was more than double the revenue seen in the previous quarter of just over $625,000. • FRX posted a quarterly loss of $0.02 per share, slightly ahead of our estimates due largely to an improvement in the gross margin. • Gross margins improved to a gain of ...LEXX: GLP-1s’ Sweet Opportunity. Lexaria Bioscience Corporation (NASDAQ:LEXX) reports fiscal full year 2023 results along with program updates, new deals and a small capital raise since the third quarter report in August. The company announced that the investigational new drug (IND) application would be delayed on account of a supplier.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Highlights for 2022 and to-date include: TLANDO approved – March 2022. LPCN 1144 end of Phase II meeting with FDA – July 2022. LPCN 2101 IND cleared – July 2022. LPCN 1154 (post-partum depression) pathway to approval clarified – September 2022. Strategic realignment towards CNS disorders – September 2022.Find top rated mutual funds and information to help you beat the market. Explore mutual fund resources, portfolios, and mutual fund commentary at Zacks.

Nov 13, 2023 · By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo (NASDAQ:ONVO) reported its fiscal 2Q earnings and results were roughly inline with our expectations and illustrate to us that the company continues to progress toward bringing important products to market. Specifically, the company reported: • Earnings of -$0.46 per share, in line with estimates as expenses remained Zacks Equity Research November 23, 2023. CVX Quick Quote CVX ... Overall, they are usually a stable option, with less risk and more sure-fire cash flows than …

Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. 1. Reviva RECOVER Topline Results Data Presentation, October 30, 2023.Apr 17, 2023 · Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. 1. Screenshot of interview with Allarity CEO, Jim Cullem. 2. By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Phase 2b Data for EB01 in January 2023 Edesa Biotech, Inc. (NASDAQ:EDSA) is currently conducting a double blind, placebo controlled trial to evaluate the safety and efficacy of 2.0% EB01 cream in approximately 170 evaluable subjects in …© Zacks Small Cap Research - All rights reserved Powered By Q4 Inc. 5.111.2.6 (opens in new window) 5.111.2.6 (opens in new window)SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

Sep 2, 2022 · Results from the second bioequivalence study were shared with investors a few weeks ago on August 22, 2022. The data demonstrated pharmacokinetic equivalence between 5 mg of Alpha-1062 delayed release tablets and 8 mg galantamine hydrobromide extended release (ER) capsules. These results combined with the data released in June show that both ...

Zacks Small Cap Research coverage specifically looks to focus on small and micro-cap companies that are under followed or under valued by Wall Street. Our analysts seek to identify and report...

Forgot your password? Email us at [email protected] for assistance ...By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Phase 2b Data for EB01 in January 2023 Edesa Biotech, Inc. (NASDAQ:EDSA) is currently conducting a double blind, placebo controlled trial to evaluate the safety and efficacy of 2.0% EB01 cream in approximately 170 evaluable subjects in total suffering from chronic allergic contact dermatitis (ACD) (NCT03680131).By Thomas Kerr, CFA. NASDAQ:GRIL. READ THE FULL GRIL RESEARCH REPORT. Muscle Maker Inc. (NASDAQ:GRIL), has evolved into a diversified, global food company with two distinct business units: 1) Sadot LLC – an international agricultural commodity supply-chain organization and 2) MMI Restaurant Group – an operator and franchisor of 50+ healthier-for-you fast casual concepts plus a subscription ...Zacks Small-Cap Research Tom Kerr 312-265-9147 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 November 14, 2022 UPDATE: Siyata reported 2022 3rd quarter financial results which showed high revenue growth rates compared to the prior year period. Utilizing a DCF valuation process containingWhen it comes to maintaining and enhancing the appearance of your vehicle, even the smallest details matter. One such detail that often goes overlooked is the wheel center caps. These small, circular covers not only add a touch of style to ...The Zacks Small/Mid Cap Core Portfolio (SMIZ) ETF represents the combination of our Small and Mid Cap separately managed accounts (SMAs), drawing upon over a decade of comprehensive research and analysis. Utilizing the Zacks Proprietary Multi-factor Alpha Model, our portfolio management team identifies a selection of the …3 Top-Ranked Beaten-Down Tech Stocks to Buy... AWS 10/6: Jobs Numbers Double to 336K on... PFP 10/6: All Eyes on This Morning's Jobs... Top Stock Reports for Alphabet, Sanofi &... A complete...

In the financial sphere, Protalix generated revenues of $6.4 million in 2Q:21 compared to revenue of $11.0 million in the prior year period. This resulted in net loss of ($11.2) million versus loss of ($4.2) million in 2Q:20. Financial results for the quarter ending June 30, 2021 compared to the quarter ending June 30, 2020:By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT Fourth Quarter and Fiscal Year 2021 Financial and Operational Results On March 15, 2022, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) announced fourth quarter and fiscal year 2021 financial and operational results and filed …Zacks Small-Cap Research Sponsored – Impartial - Comprehensive Lisa Thompson 312-265-9517 [email protected] Sponsored – Impartial - Comprehensive …Raises Gross Proceeds of $55 Million to Advance Lead Compound to Clinical Trials. On My 17, 2023, Satellos Biosciences Inc. (OTC:MSCLF) announced it closed an equity offering in which it raised gross proceeds of $55 million from the issuance of 110 million equity securities at $0.50 per common share or pre-funded warrant (70,297,220 common ...Zacks Rank N/A BIOR: Precision Release – Surgical Strike on the GI Tract Zacks Small-Cap Research Joh Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. …Investrade has good news to share - we are providing all customers FREE Snapshot research reports from Zacks Investment Research. There are reports on 4400 ...By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT We are initiating coverage of Abeona Therapeutics Inc. (NASDAQ:ABEO) with a valuation of $10.00. Abeona is a biopharmaceutical company developing cell and gene therapies for rare genetic diseases. Its lead clinical program, EB-101, is an autologous cell therapy in development for the treatment of recessive dystrophic epidermolysis

Nine analysts revised their earnings estimate higher in the last 60 days for fiscal 2023, while the Zacks Consensus Estimate has increased $0.78 to $16.84 per …

Zacks Rank N/A FY21 Results; IO Revenues Analysis Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 January 11, 2022 312-265-9588 / [email protected] Revenue Q1 Q2 Q3 Q4 Year (Dec) (Mar) (Jun) (Sep) (Sep)The Zacks Small/Mid Cap Core Portfolio (SMIZ) ETF represents the combination of our Small and Mid Cap separately managed accounts (SMAs), drawing upon over a decade of comprehensive research and analysis. Utilizing the Zacks Proprietary Multi-factor Alpha Model, our portfolio management team identifies a selection of the …By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update AdCom Granted for NurOwn® On March 27, 2023, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced that the U.S. Food and Drug Administration (FDA) has granted an Advisory Committee (AdCom) meeting to discuss …By Brad Sorensen, CFA OTC:CLMEF READ THE FULL CLMEF RESEARCH REPORT We are reiterating are positive view on Calima Energy (OTC:CLMEF) and urging investors to take a look at a company with an in-demand asset that is well run, cares about shareholders, and is trading well below our conservative valuation of $0.55/share. …Zacks Small Cap Research. TENX: Notice of Allowance Increases Confidence. Read full article. Zacks Small Cap Research. June 23, 2023 at 3:24 AM ...When it comes to wheels, one small but important component that often goes unnoticed is the wheel center cap. These caps not only add a touch of style to your vehicle’s wheels but also serve several practical functions.

By Brad Sorensen, CFA OTC:CLMEF READ THE FULL CLMEF RESEARCH REPORT We are reiterating are positive view on Calima Energy (OTC:CLMEF) and urging investors to take a look at a company with an in-demand asset that is well run, cares about shareholders, and is trading well below our conservative valuation of $0.55/share. …

John Vandermosten, CFA is currently a Senior Analyst for Zacks Investment Research where he covers a portfolio of small cap biotechnology names. His background includes 19 years of experience in a variety of investment management and research roles across all market cap ranges and throughout the capital structure. John is a frequent moderator ...

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …3 Top-Ranked Beaten-Down Tech Stocks to Buy... AWS 10/6: Jobs Numbers Double to 336K on... PFP 10/6: All Eyes on This Morning's Jobs... Top Stock Reports for Alphabet, Sanofi &... A complete...The details of 2Q 2023: • Revenue for the quarter came in at $1,480,388, which was more than double the revenue seen in the previous quarter of just over $625,000. • FRX posted a quarterly loss of $0.02 per share, slightly ahead of our estimates due largely to an improvement in the gross margin. • Gross margins improved to a gain of ...By Thomas Kerr, CFA NASDAQ:UXIN READ THE FULL UXIN RESEARCH REPORT On December 30th, Uxin (NASDAQ:UXIN) reported fiscal 2nd quarter operating and financial results for the three-month period ending September 30, 2022. Total revenues increased to $87 million which was a 1.2% increase from the fiscal 1st quarter and a 78.9% increase from the prior year period. Unit volume was 6,050 vehicles in theZacks Small-Cap Research Sponsored – Impartial – Comprehensive November 8, 2023 John D. Vandermosten, CFA scr.zacks.com 312-265-9588 / [email protected] …Research Reports. Companies by Analyst. Steven Ralston, CFA; David Bautz, PhD; Ann Heffron, CFA, CPA; Thomas Kerr, CFA; Brian Lantier, CFA; M. Marin; Brad Sorensen, …By M. Marin NASDAQ:NVX | OTC:NVNXF READ THE FULL NVX RESEARCH REPORT Company positioning to benefit from ramping growth in target verticals Novonix (NASDAQ:NVX) (OTC:NVNXF) has a positive sector tailwind, in our opinion, as it advances its strategy to develop a U.S.-based lithium-ion battery materials …By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates In July 2022, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced the first subjects were dosed in two Phase 1/2a clinical trials of ARO-RAGE and ARO-MUC5AC, which are the company’s investigational candidates designed as potential treatments

On May 9, 2023, Lantern Pharma, Inc. (NASDAQ:LTRN) announced 2022 financial and operational results, filed its Form 10-Q with the SEC and hosted a video webcast to review accomplishments. In the last six weeks, Lantern has dosed its first patient in the Phase II Harmonic study, announced receipt of a patent allowance by the USPTO …Net R&D expenses for the third quarter of 2023 were $3.3 million, compared to $3.8 million during the third quarter of 2022. The decrease was primarily due to decreased costs related to the Phase 3 clinical trial and decreased payroll expense, travel, materials, depreciation, and other activities. G&A expenses for the third quarter of 2023 were ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …The TSP-21-G form is the loan agreement form individuals sign when they borrow against their Thrift Savings Plan accounts, according to the U.S. Government Publishing Office. TSP loans are only available to current military and federal empl...Instagram:https://instagram. anhaiser bushunreal engine macbookvalue of 1921 morgan dollarbest currency trading sites Institutional Distribution. A 15-20 page, fully entitled research report, produced within 3-4 weeks that targets the institutional investor, currently distributed to First-Call, Capital IQ, Bloomberg, FactSet, and our own ZRS Platform. Together, these platforms target over 20,000 institutional investors and 90% of all asset and hedge fund managers.Mar 3, 2023 · By Brad Sorensen, CFA OTC:FRXIF READ THE FULL FRXIF RESEARCH REPORT Demand continues to increase for a flame retardant that doesn’t have toxic chemicals and the Nofia product from FRX Innovations (OTC:FRXIF), an eco-friendly flame retardant solution, is the perfect solution. Studies previously cited by the FRX note that over 60% of fire-retardant plastic formulations are based on what happened to tesla stockwhat is a penny stock broker David Bautz, PhD, Senior Analyst for Zacks Small-Cap Research, with 9 years of direct experience in the securities and investment industry. David’s research articles have been posted extensively on Yahoo Finance News and throughout life sciences social media circles. Prior to joining Zacks in 2014, David was an NRSA postdoctoral fellow ...Apr 18, 2023 · By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT We are initiating coverage of Abeona Therapeutics Inc. (NASDAQ:ABEO) with a valuation of $10.00. Abeona is a biopharmaceutical company developing cell and gene therapies for rare genetic diseases. Its lead clinical program, EB-101, is an autologous cell therapy in development for the treatment of recessive dystrophic epidermolysis ai c3 stock price SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …The following disclosures relate to relationships between Zacks Small-Cap Research ( Zacks SCR ), a division of Zacks Investment Research ( ZIR ), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe. ANALYST DISCLOSURES. Zacks SCR Analysts hereby certify that the view expressed in this research report or article ...Management reiterated its outlook of revenues between $14.0 and $15.0 million in 2023. Operational and scientific highlights for 2Q:23 and to date include: Import license granted for Indonesia, Malaysia and South Africa – April 2023. Teijin license fee remitted – April 2023. Three patent issue notifications received – April 2023.